How Much Evidence Is Enough Before a Biotech Decision?

TL;DR: Choose a review scope around the biotech decision, with a map of search coverage, study independence and remaining uncertainty.

A strong scientific review is not defined by how many papers it reads. It is defined by the decision it can support, and by how clearly it shows what remains unknown.

Why this matters: a biotech founder, R&D lead or investment reviewer needs to know what a review can support before committing the next budget.

A biotech team may have a persuasive biological target, a set of promising experiments and a costly next step ahead. It needs an answer to a deceptively simple question: Is the evidence strong enough to make that investment?

There is no magic number of publications that answers it.

Reading a small group of well-chosen papers can expose a broken causal link. Reading hundreds of papers can still miss a crucial negative study, count the same trial several times, or confuse what a drug does with what a single biological target causes.

The useful question is not “How many papers did you read?” It is “What evidence did the decision require, how thoroughly did you look for it, and what would change your conclusion?”

Three different jobs, three different review scopes

1. A rapid research triage asks whether a proposed direction deserves further attention. It may check the most relevant public sources, obvious prior work, and known contradictions. It is useful for narrowing options. It does not claim to cover all eligible evidence.

2. A focused falsification challenge asks whether a particular claim survives targeted attempts to break it. The team specifies one mechanism or causal claim, the context and the next decision. Reviewers look for missing links, independence failures and contrary results. This can produce an important warning quickly. But it is still a bounded challenge: an unexamined part of the literature remains unexamined.

3. A decision-grade evidence assessment asks whether the available evidence is sufficient for a defined consequential decision. Its search coverage and depth are set by the question and risk, not by a fixed document count. It may require multiple databases, trial registries, regulatory materials, study-level deduplication, full-text assessment, formal risk-of-bias review and qualified specialist judgment.

Here, "decision-grade" is our editorial description of fitness for a stated decision, not a certification or a named review standard. Such an assessment might use a full systematic review or a documented targeted synthesis. Do not call either one systematic unless its methods meet the applicable standards. PRISMA 2020 (S2) covers reporting, including search strategies, selection and exclusions. It is not a quality certification. The Cochrane Handbook (S1) explains the need for broad, reproducible searches.

These three scopes are an editorial framework, not new service packages. They solve different problems. A short challenge can show why a larger review is needed. A larger review is justified when missing a relevant study could materially change the decision.

The hidden problem with a paper count

Imagine an illustrative dossier with twelve relevant-looking documents. Four discuss one clinical trial, three describe different experiments from one laboratory, two report on overlapping patient samples, and three are unrelated studies.

That is twelve documents, not twelve independent confirmations. The numbers in this example are invented only to illustrate the logic; they are not a finding from a real drug program.

Before counting evidence, ask:

• What is the study? Link the journal paper, preprint, registry record, conference abstract and secondary analysis to their underlying study.
• Which people, samples or experimental systems overlap? Two reports from the same population are not independent replication.
• What was actually measured? A receptor-binding assay, a genetic association and a human clinical outcome answer different questions.
• Was the comparison fair? Different populations, doses, follow-up periods and outcome definitions can prevent a meaningful comparison.
• What was searched and what was not? Record databases, dates, exact search terms, eligibility rules and important coverage gaps.

Cochrane explicitly treats studies rather than reports as the unit of inclusion and recommends linking multiple reports of one study. Counting publications alone can exaggerate the appearance of convergence.

A practical evidence-to-decision map

For every important claim, a team should be able to complete five lines:

This is not a checklist to produce an impressive-looking score. It is a way to make the evidence boundary visible.

A review that cannot fill the last line may be more dangerous than one that admits a gap: it can leave executives with a confident narrative and no way to test the confidence.

When “not evaluable” is an actionable result

Sometimes the evidence supports several pieces of a biological story but cannot test the bridge between them. The correct result may be not evaluable, rather than “supported” or “disproven.”

That answer can still improve a decision. It can show that another literature summary will not resolve the uncertainty and that a particular measurement, comparator or independent dataset is the missing piece.

In one of our prospective public-data experiments, an initially plausible biological mechanism was not promoted because the necessary human-genetic causal bridge was not evaluable. Our published case study explains the limits. It is our own research, published as a preprint, not peer reviewed or externally validated.

The point is not that the mechanism was false. It is that the evidence had not earned a stronger conclusion.

How to commission the right review

Before asking for a fee or timeline, give the researcher the decision and ask for a scope that explicitly states:

1. Decision and question: Which action might change as a result of the report?
2. Evidence boundary: Which public sources may be accessed, and under what rights?
3. Coverage standard: Is this targeted falsification, a mapped evidence landscape or a reproducible comprehensive review?
4. Independent checks: How will duplicate studies, contrary findings and source-level errors be challenged?
5. Stop conditions: What would make the question unanswerable from the available evidence?
6. Deliverables: A readable conclusion, cited evidence map, conflicts, limitations and the next discriminating evidence.
7. Change control: What happens if the necessary search is larger than the initial scope?

The last item is important. Scientific completeness cannot be promised simply by increasing speed. If the corpus is much broader than expected, the right response is to revise the scope or be explicit that the result is preliminary.

The decision is the unit of value

A good scientific assessment may recommend proceeding, reworking the rationale, pausing for a particular experiment, or deciding that available evidence cannot answer the question. None of these outcomes is an automatic prediction of clinical success.

At Biodius, our Target Challenge is deliberately a bounded way to stress-test one claim. It is not a substitute for a comprehensive evidence review. Our technical preprint describes what our own prospective experiments did and did not establish.

If you face a costly scientific decision, start with that decision and the evidence it would require. Then choose the scope. A useful review makes the decision clearer, even when the answer is that more evidence is needed.

For an initial fit discussion, contact First AI Movers / Biodius. Share only information you are authorized to share.

Frequently asked questions

Does a longer bibliography mean a better review?

Not by itself. Check whether reports describe different underlying studies, whether the evidence addresses the decision, and which sources the search could have missed.

Is a focused challenge a systematic review?

No. A bounded challenge tests a defined claim within a declared scope. A systematic review requires the appropriate search, selection and synthesis methods; a reporting checklist alone does not confer that status.

What should happen when the scope is too small?

State the gap, describe which conclusion it prevents, and agree whether to expand the work. A preliminary finding should retain its preliminary label.

Read further

• When an evidence gap is a useful result
• Our public account of the preprint and its limits
• About First AI Movers and its editorial perspective
• Biodius Target Challenge FAQ: Scope, Inputs, Price and Limits

Our source is Costa (2026), Falsification-First AI for Biological Target Assessment: Lessons from Four Prospectively Frozen Experiments, DOI 10.5281/zenodo.23057911 (S3). This preprint is not peer reviewed and has not been externally validated; it establishes no diagnostic, therapeutic, safety or predictive claim.

AI assistance was used for drafting, source checks and editing. Human editorial responsibility remains with First AI Movers.